Ottimo Pharma Emerges With An Ex-Seagen CEO And A PD1/VEGF Bispecific Contender

 
• By Andrew McConaghie

It is chasing Summit and other companies in the PD1/VEGF field, but Ottimo’s CEO David Epstein believes it has a unique drug design – plus a clear plan for a big pharma buyout

Cancer cells on scientific background.3d illustration
• Source: Shutterstock

More from Start-Ups & SMEs

More from Scrip